vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and 10x Genomics, Inc. (TXG). Click either name above to swap in a different company.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
10x Genomics, Inc. is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | — | ||
| Q3 25 | $52.3M | — | ||
| Q2 25 | $45.6M | — | ||
| Q1 25 | $41.5M | — | ||
| Q4 24 | $57.5M | — | ||
| Q3 24 | $51.5M | — | ||
| Q2 24 | $46.6M | — | ||
| Q1 24 | $44.9M | — |
| Q4 25 | $-44.1M | — | ||
| Q3 25 | $-5.5M | — | ||
| Q2 25 | $-5.6M | — | ||
| Q1 25 | $-11.4M | — | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $941.0K | — | ||
| Q2 24 | $-10.4M | — | ||
| Q1 24 | $-6.2M | — |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | — | ||
| Q3 25 | -17.6% | — | ||
| Q2 25 | -23.3% | — | ||
| Q1 25 | -36.1% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | -8.2% | — | ||
| Q2 24 | -18.3% | — | ||
| Q1 24 | -23.9% | — |
| Q4 25 | -70.9% | — | ||
| Q3 25 | -10.5% | — | ||
| Q2 25 | -12.2% | — | ||
| Q1 25 | -27.5% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | -22.4% | — | ||
| Q1 24 | -13.8% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
